Not Tagged
amgen
['lung', 'amgen']
 at asco 2019 amgen presented an analysis of the first 10 evaluable participants with lung cancer. * 5 experienced partial shrinkage of the tumor and 4 had stable disease with no further progression. * one of the partial responders had a complete response with longer follow-up.